SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is drawing attention as cybersecurity stocks outperform, with traders pointing to an Evercore channel survey indicating firming security budgets and spending on identity and AI security; recent AI-related vulnerability headlines also feature in the discussion. Bullish traders cite the sectors strength, while skeptics argue the rally is excessive given the stocks high valuation.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Ubers continued share-price weakness is fueling frustration, with traders debating whether robotaxi competition and the departure of its autonomous-mobility chief threaten its strategy. Others argue the market is overlooking the profitable core business and Ubers potential role connecting riders with autonomous fleets, while upcoming earnings are seen as an important test.

Maplebear, Inc. engages in the design and development of an online application that offers grocery delivery and pick-up services. The firm offers Instacart which enables users to connect with personal shoppers in the area who pick up and deliver groceries from local stores. The company was founded by Apoorva Mehta, Brandon Leonardo, and Max Mullen in 2012 and is headquartered in San Francisco, CA.

Maplebear Inc.

Instacart

Reports that Instacart is exploring a sale and has held preliminary takeover talks with Uber and DoorDash are driving attention. Traders are reacting to the potential buyout, though some question whether a deal will happen and flag competition and regulatory hurdles.

Palo Alto Networks, is a cybersecurity company that provides cybersecurity platforms and services to enterprises, organizations, service providers, and government entities. Its offerings include network and AI security, cloud security, security operations, and identity security solutions. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Cybersecurity shares rallied after an Evercore ISI channel survey indicated enterprise security budgets are firming, with spending directed toward identity and AI security; escalating vulnerability reports also reinforced the demand theme. Traders welcomed PANWs relative strength, though some remain cautious about its rich valuation and earnings-related volatility.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

PHAT is drawing attention after BDR Pharmaceuticals sued the FDA over VOQUEZNAs exclusivity, raising concern that generic competition could arrive earlier and weighing on the shares. Traders are divided: bears see a lingering legal overhang, while bulls stress the suit targets the FDAnot Phathomand does not mean a generic application has been accepted or competition approved.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies amid Middle East and Iran tensions, with traders focused on the risk that renewed conflict could disrupt oil supplies. The community is divided between bulls citing supply risks and breakout momentum and bears calling the move overextended or vulnerable to a reversal if tensions ease.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is rising alongside a broader cybersecurity-sector rally, with traders also citing analyst price-target increases and new autonomous-security products highlighted at its OneCon conference. Some see company-specific momentum in the AI offerings, while others say the move largely tracks gains across the sector.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, and Defense. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

The sharp pullback is being linked by traders to broader aerospace-sector weakness, rising oil and jet-fuel concerns, and Safran comments suggesting softer widebody-market growth; some also point to geopolitical and macro volatility. The community is divided between viewing the decline as an overreaction with Rolls-Royces fundamentals intact and expecting further downside after the stocks run-up.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

The FDA accepted Biohavens resubmitted Vyglxia (troriluzole) application for spinocerebellar ataxia, setting a Q1 2027 decision goal and planning an advisory committee review; the update sparked excitement about a potential first commercial product. Traders remain divided, with some viewing the acceptance as a meaningful second chance and others stressing it is not an approval and that the FDAs earlier concerns remain relevant.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels clinical pipeline is driving attention, particularly its planned prostate-cancer BLA submission and newly discussed NSCLC and glioblastoma data. Bullish traders see the results and regulatory progress as validation, while others focus on the share-price decline, CEO stock sales, possible dilution, and weakness across biotech.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)PR NewswireNEWTON, Mass., Oct. 1, 2026NEWTON, Mass., Oct. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a...

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON, Mass., Sept. 1, 2026 NEWTON, Mass., Sept. 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq...

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis PR Newswire NEWTON, Mass...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 27, 2026 NEW YORK, Aug. 27, 2026...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 20, 2026 NEW YORK, Aug. 20, 2026...

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -51.63% and +5.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission PR Newswire NEWTON, Mass., Aug. 13, 2026...

Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -80.00% and +12.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 PR Newswire NEWTON, Mass., Aug. 10, 2026 -- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET --NEWTON, Mass., Aug. 10...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026...

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A. Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Karyopharm Therapeutics Inc

Why Is KPTI Stock Down 69% After-Hours Today?

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer.</li><li>Company officials said they were disappointed by the unexpected outcome and will cut planned spending on the endometrial cancer program.</li><li>Chief Executive Richard Paulson said that the company remains focused on its myelofibrosis program.</li></ul> Shares of Karyopharm Therapeutics (KPTI) fell 69% in after-hours trading on Thursday after the biotech company reported that its drug selinexor failed to delay disease progression meaningfully in endometrial cancer in a late-stage clinical trial. &nbsp;<h2 class="st-heading-2">What Did The Trial Show?</h2>The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer. It did not show a statistically significant delay in disease progression. A trend toward longer progression-free survival was seen in a key patient group—roughly 13 months for those on selinexor versus about 7.5 months on placebo—but the difference did not reach the required threshold for success, the company said.Safety results matched the drug’s known profile, the company said, with no new concerns identified. Company officials said they were disappointed by the unexpected outcome and will cut planned spending on the endometrial cancer program while completing a full data review for presentation at a future medical meeting. They plan to keep following patients for longer-term survival results.<h2 class="st-heading-2">KPTI’s Steps Ahead</h2>“While the results we are announcing today fell short of our expectations, they do not diminish our confidence in the broader potential of selinexor,” said Chief Executive Richard Paulson. He added that the company remains focused on its myelofibrosis program.In a separate announcement the same day, Karyopharm said it plans to submit an application to the U.S. Food and Drug Administration in August seeking accelerated approval for selinexor combined with ruxolitinib as a treatment for myelofibrosis. If cleared, the combination could become the first approved dual therapy for the rare blood cancer. The company intends to request priority review, which could lead to a decision about six months after submission.Paulson called the planned filing a potentially transformative step for patients and for the company.Selinexor, sold as Xpovio, is already FDA-approved for treating multiple myeloma in certain adult patients. Karyopharm reported U.S. XPOVIO (selinexor) net product revenue of $114.9 million for the full year 2025, accounting for a major portion of the company’s overall revenue. &nbsp;However, earlier this year, the FDA withdrew selinexor’s accelerated approval for a type of lymphoma after Karyopharm did not complete a required confirmatory trial, reducing its total addressable market.<h2 class="st-heading-2">How Did KPTI Retail Traders React?</h2>On Stocktwits, retail sentiment around KPTI rose from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume stayed at normal levels.A Stocktwits user said that partnerships may help the company continue its pipeline efforts.<stembedurl>https://www.stocktwits.com/joe77w/message/660525957</stembedurl>Another dismissed the after-hours selloff, noting that the company already has approvals in place and a remaining pipeline.<stembedurl>https://www.stocktwits.com/Tea_n_crumpet_enjoyer/message/660523869</stembedurl><a href="https://stocktwits.com/symbol/KPTI">KPTI stock</a> has fallen 5% year-to-date.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/phat-stock-clocks-worst-day-in-over-1-5-years-what-sparked-the-selloff/cZN5iRSRJ2B">PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The late-stage study tested selinexor as a maintenance treatment against placebo in patients with a specific form of advanced or recurrent endometrial cancer.Company officials said they were disappointed by the unexpected outcome and will cut planned spen

Karyopharm said that a key late-stage trial of its drug selinexor in endometrial cancer failed to meet its primary goal. 


iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.5175
Prev Close	$0.5461
Open	$0.5366
Dividend Yield	0.00%
50-Day Moving Average	$1.38
Beta	0.86
Avg. Volume	1.43M
PE Ratio	-0.04

52-Week High	$10.99
52-Week Low	$0.31
Market Capitalization	$12.39M
EPS (Annual)	-$17.93
Price to Book	-0.04
Revenue Per Employee	$640,644.74

Feed

News

Sentiment

Earnings

Fundamentals

Info

KPTI Fundamentals